Linden Thomas Advisory Services LLC Buys 241 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Linden Thomas Advisory Services LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,055 shares of the biopharmaceutical company’s stock after buying an additional 241 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $2,176,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. AE Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 19.4% in the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock valued at $575,000 after acquiring an additional 89 shares in the last quarter. Public Sector Pension Investment Board lifted its position in shares of Regeneron Pharmaceuticals by 77.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 3,841 shares of the biopharmaceutical company’s stock valued at $4,037,000 after buying an additional 1,679 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $24,038,000. MBB Public Markets I LLC boosted its holdings in Regeneron Pharmaceuticals by 2,095.9% in the 2nd quarter. MBB Public Markets I LLC now owns 7,532 shares of the biopharmaceutical company’s stock worth $7,916,000 after buying an additional 7,189 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Regeneron Pharmaceuticals by 0.7% in the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after acquiring an additional 2,270 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $675.79 on Friday. The firm has a market capitalization of $74.26 billion, a PE ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10. The firm has a 50 day moving average of $727.19 and a two-hundred day moving average of $937.77. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.